CYRAMZA may help starve cancerous tumors
As an anti-angiogenic, CYRAMZA works differently from traditional chemotherapy—but can partner with your chemotherapy to fight colorectal cancer by acting on a source of your cancer’s growth.
CYRAMZA may work as a tumor-starving agent to attack your cancer. Tumors need nutrients to grow, which are mainly supplied through your blood vessels. CYRAMZA is thought to stop new blood vessels from forming, including those that feed your tumor. This may help starve the tumor of the nutrients it needs to keep growing.*
See below for how CYRAMZA is thought to work.
CYRAMZA was shown to interfere with angiogenesis which may slow tumor growth
*The process of how CYRAMZA is thought to work was shown in laboratory studies.
- Without treatment
- With treatment
Without treatment
- Tumor sends out signals asking certain receptors to build new blood vessels
- Receptors receive the signals
- Development of new blood vessels begins, which may mean more nutrients for your tumor
With CYRAMZA
- Tumor sends out signals asking certain receptors to build new blood vessels
- CYRAMZA blocks the formation of new blood vessels, including those that feed your tumor
- Limiting the development of new blood vessels may mean fewer nutrients for your tumor
You don’t need a specific biomarker in order to receive CYRAMZA.
Talk to your doctor about whether CYRAMZA is right for you.
CYRAMZA is used with a chemotherapy combination called FOLFIRI to treat metastatic colorectal cancer in patients whose cancer has progressed after being treated with other certain types of chemotherapy.
Explore Lilly PatientOne for information on savings and financial assistance.